27 Agents Or Agent Classes With Antibiofilm Activity
Important distinction: only a minority have strong evidence for treating established biofilm infections in humans. Many are useful only at specific sites—implants, catheters, wounds, lungs, sinuses, oral cavity, or root canals—and some remain preclinical. In most deep infections, drainage, debridement, or removal of infected hardware is more important than adding a “biofilm supplement.”
A. Clinically Established Or Supported In Selected Infections
| # | Agent | Main Role And Evidence |
|---|---|---|
| 1 | Rifampin / rifampicin | Among the best-supported antibiotics for susceptible staphylococcal biofilms on retained orthopedic or other hardware. It must usually be combined with another active antibiotic because monotherapy rapidly selects resistance. |
| 2 | Fluoroquinolones—ciprofloxacin, levofloxacin | Good tissue penetration and activity against susceptible Gram-negative biofilm organisms; commonly paired with rifampin for selected susceptible staphylococcal device infections. Toxicity and resistance limit indiscriminate use. |
| 3 | Daptomycin | Bactericidal against susceptible Gram-positive organisms, including stationary-phase staphylococci and enterococci. Used in selected bloodstream, endovascular, bone, joint, and device infections, frequently in combination rather than as a generic biofilm drug. |
| 4 | Vancomycin | Standard agent for many methicillin-resistant Gram-positive infections, but penetration and killing within mature biofilms may be incomplete. Source control remains essential. |
| 5 | Linezolid | High oral bioavailability and tissue penetration; useful against susceptible staphylococci and enterococci. Long courses can cause cytopenias, neuropathy and important drug interactions. |
| 6 | Fosfomycin | Demonstrates matrix penetration and combination activity against some Gram-positive and Gram-negative biofilms. Clinical utility depends on infection site, formulation, organism and susceptibility. |
| 7 | Macrolides—azithromycin, clarithromycin | May inhibit quorum signaling, alginate production and inflammatory injury, especially in chronic Pseudomonas airway disease. They are not reliably bactericidal against Pseudomonas itself. |
| 8 | Inhaled tobramycin or other inhaled antibiotics | Produce high local airway concentrations in selected patients with chronic or newly acquired Gram-negative airway infection. This is a lung-specific strategy, not systemic biofilm therapy. |
| 9 | Mupirocin | Topical activity against susceptible staphylococci, especially nasal colonization and selected superficial infections. Resistance can develop with repeated or prolonged use. Laboratory activity against established staphylococcal biofilms has been demonstrated. |
| 10 | Taurolidine | Used principally in selected catheter-lock solutions to prevent recurrent catheter-related bloodstream infections. It has antimicrobial and antibiofilm activity without relying on a conventional antibiotic. |
| 11 | Citrate catheter locks | Chelates calcium and can reduce catheter colonization; frequently combined with taurolidine or other lock ingredients. This is a catheter-specific intervention and should use validated formulations. |
B. Matrix-Disrupting Or Biochemical Adjuncts
| # | Agent | Main Role And Evidence |
|---|---|---|
| 12 | N-acetylcysteine—NAC | Disrupts extracellular polymeric material, reduces bacterial adhesion and acts as a mucolytic. Human studies suggest possible adjunctive value in selected respiratory, gastrointestinal and device settings, but oral NAC has not been proven to eradicate deep systemic biofilms. |
| 13 | EDTA | Chelates calcium, magnesium and iron that help stabilize some matrices; can increase permeability and antibiotic activity. Most defensible uses are local, dental, wound or catheter-lock applications—not unrestricted intravenous or oral “chelation for biofilms.” |
| 14 | Dornase alfa / DNase I | Degrades extracellular DNA, an important structural component of many biofilms. Dornase has an established inhaled role in cystic fibrosis, but systemic biofilm eradication has not been established. |
| 15 | Alginate lyase | Degrades alginate in mucoid Pseudomonas matrices and may improve antibiotic access. Promising primarily in preclinical or delivery-system research; not routine systemic treatment. |
| 16 | Dispersin B | Enzyme that cleaves poly-N-acetylglucosamine in biofilms made by some staphylococci and other bacteria. Strong experimental rationale, but limited human therapeutic evidence. |
| 17 | Proteolytic enzymes—for example trypsin or proteinase K in research | Can degrade protein components of selected matrices. Their effectiveness is organism-specific, and systemic commercial enzyme supplements have not been shown to reproduce laboratory biofilm concentrations. |
| 18 | Lactoferrin | Sequesters iron and may alter bacterial motility, attachment and biofilm maturation. Human clinical evidence as a treatment for established biofilm infection remains limited. |
| 19 | Nitric-oxide donors | Low nitric-oxide concentrations can trigger biofilm dispersal, while higher local concentrations may be bactericidal. Gels, coatings and inhaled/local systems are under investigation; they are not yet general systemic treatment. |
| 20 | Bismuth compounds | Can interfere with microbial enzymes, adhesion and matrix formation and may enhance certain antibiotics. Clinical application is limited by formulation, organism, site and toxicity concerns. |
C. Topical Antiseptics And Wound-Directed Agents (Just To Orient On The Longest Ways Biofilms Are Removed)
| # | Agent | Main Role And Evidence |
|---|---|---|
| 21 | Cadexomer iodine | One of the better-supported topical wound agents. It absorbs exudate and releases iodine gradually. Comparative clinical studies found reductions in slough, bioburden and infection and improved healing outcomes, although not every benefit can be attributed specifically to biofilm eradication. |
| 22 | Polyhexamethylene biguanide—PHMB | Topical antiseptic used in wound cleansers and dressings. It has broad antimicrobial activity and laboratory antibiofilm effects, but product formulation and tissue compatibility matter. |
| 23 | Hypochlorous acid / dilute hypochlorite formulations | Oxidizing topical antimicrobials used for wound cleansing in controlled formulations. Concentration is crucial because excessive exposure can damage host tissue. They should not be improvised from household bleach. |
| 24 | Silver dressings or ionic silver | Broad topical antimicrobial activity and activity against some wound biofilms. Clinical benefit varies significantly among dressings and wound types; silver is generally used for limited periods when local bacterial burden is a concern. |
| 25 | Medical-grade honey | Provides osmotic, acidic and peroxide/non-peroxide antimicrobial effects. Human wound literature supports selected medical-grade products for wound management, while much of the explicit antibiofilm evidence remains laboratory based. Kitchen honey should not be placed in wounds. |
| 26 | Acetic acid | Particularly interesting for topical management of Pseudomonas-colonized wounds. It can be antimicrobial and antibiofilm at controlled concentrations, but may be painful or cytotoxic if improperly formulated. |
| 27 | Chlorhexidine | Widely used for skin, oral and catheter-site antisepsis. It is helpful for prevention and superficial control, although mature biofilms can be much less susceptible than planktonic bacteria. It should never be introduced into the eye, middle ear, brain or other inappropriate compartments. |
Important Emerging Treatments
Bacteriophages deserve a separate category. Phages may infect bacteria inside biofilms, and some produce depolymerases that degrade the matrix. Case series and early clinical experiences are encouraging for complex orthopedic, wound and device infections, especially when combined sequentially with antibiotics, but phage selection is highly strain-specific and treatment remains specialized or investigational in many countries.
Other experimental groups include antimicrobial peptides, quorum-sensing inhibitors, cyclic-di-GMP modulators, nanoparticles, biosurfactants, persister-cell agents and engineered lysins. A 2024 systematic review found that most studies of experimental antibiofilm agents were still preclinical and focused more on laboratory efficacy than human safety.
Practical Evidence Ranking
Strongest Clinical Foundation
- Surgical or mechanical source control
- Removal or exchange of infected devices when indicated
- Culture-directed antibiotics
- Rifampin combinations for selected susceptible staphylococcal hardware infections
- Local delivery appropriate to the site
- Debridement plus validated wound antiseptics for chronic wounds
Reasonable Site-Specific Adjuncts
NAC, dornase, EDTA-containing local formulations, taurolidine/citrate locks, cadexomer iodine, PHMB, medical-grade honey, silver, acetic acid and controlled hypochlorous products.
Some Think These Are “Mostly Experimental”
Alginate lyase, dispersin B, systemic proteolytic enzymes, lactoferrin, nitric-oxide donors, quorum inhibitors, antimicrobial peptides, nanoparticles and many botanical compounds.
No oral combination of NAC, enzymes, EDTA, herbs or essential oils has been demonstrated to reliably eradicate a deep human bacterial biofilm. The organism, anatomical site, foreign material, antimicrobial susceptibility, vascular supply and ability to perform source control determine the appropriate treatment.